Key result
Enalapril and losartan equally normalized minimal LV coronary vascular resistance compared to placebo (9.2 and 8.8 vs 12.7 mm Hg.mL-1.min-1.g-1; P<0.05) in a rat model of myocardial infarction.
Why the study?
Does enalapril or losartan improve cardiac remodeling and coronary vascular resistance in a rat model of myocardial infarction?
RCT (n=35)
randomized
Does enalapril or losartan improve cardiac remodeling and coronary vascular resistance in a rat model of myocardial infarction?
Absolute Event Rate: 9.2% vs 12.7%
p-value: p=< .05
Both ACE inhibition and AT1 receptor blockade are equally effective in preventing ventricular remodeling and restoring coronary vascular resistance after myocardial infarction in rats.
No takes yet. Share an insight, caveat, or question.
Both normalized coronary resistance equally in rat MI; hypothesis-generating for human remodeling, requires clinical trials.
Schieffer et al. (1994) conducted an RCT in Myocardial infarction and failure (rat model) (n=35). Enalapril and Losartan vs. Placebo and Sham was evaluated on Minimal LV coronary vascular resistance (p=< .05). Enalapril and losartan equally normalized minimal LV coronary vascular resistance compared to placebo (9.2 and 8.8 vs 12.7 mm Hg.mL-1.min-1.g-1; P<0.05) in a rat model of myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: